Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LIG1 | P18858 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.41 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822715 | 0.87 | HPGD (0.51) | HPGDTSHRMAPK1HSD17B10LIG1 | |
| SCHEMBL978930 | 0.82 | HPGD (0.50) | HPGDTSHRMAPK1HSD17B10LIG1 | |
| 1-Hydroxy-2-Allyloxybenzene SCHEMBL1562951 | 0.81 | GAA (0.59) | HPGDTSHRMAPK1HSD17B10LIG1 | |
| SCHEMBL20554231 | 0.79 | TSHR (0.45) | HPGDTSHRMAPK1HSD17B10LIG1 | |
| SCHEMBL7072808 | 0.79 | HPGD (0.47) | HPGDTSHRMAPK1HSD17B10LIG1 | |
| SCHEMBL15814879 | 0.77 | CYP3A4 (0.49) | HPGDTSHRMAPK1HSD17B10LIG1 | |
| SCHEMBL4865834 | 0.77 | HPGD (0.46) | HPGDTSHRMAPK1HSD17B10LIG1 | |
| SCHEMBL11883080 | 0.77 | MEN1 (0.48) | HPGDMAPK1HSD17B10CYP3A4MAPT | |
| SCHEMBL15946499 | 0.77 | ALDH1A1 (0.41) | HPGDTSHRMAPK1HSD17B10CYP3A4 | |
| SCHEMBL4192226 | 0.76 | HPGD (0.45) | HPGDTSHRMAPK1HSD17B10LIG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368069-B | Oxazine compound, composition and cured product | DIC株式会社 | 2022-10-14 | — | — | CN | disclosed |
| CN-108473642-B | Oxazine compound, composition and cured product | DIC株式会社 | 2021-05-07 | — | — | CN | disclosed |
| US-10913725-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2021-02-09 | — | — | US | disclosed |
| US-10399312-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20180362479-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| US-20180333941-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-11-22 | — | — | US | disclosed |
| EP-3401311-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-3392281-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-10-24 | — | — | EP | disclosed |
| CN-108473642-A | Oxazine compound, composition and cured product | DIC株式会社 | 2018-08-31 | — | — | CN | disclosed |
| CN-108368069-A | Oxazine compound, composition and cured product | DIC株式会社 | 2018-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333941-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | KDM5A, PSMB5, CUL5 | HPGD 1322/4885TSHR 4872/4885MAPK1 3958/4885 |
| US-10913725-B2 | Oxazine compound, composition and cured product | PSMB5, KDM5A, CUL5 | HPGD 1165/4885TSHR 4868/4885MAPK1 3792/4885 |
| US-20180362479-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | PSMB5, KDM5A, CUL5 | HPGD 1165/4885TSHR 4868/4885MAPK1 3792/4885 |
| US-10399312-B2 | Oxazine compound, composition and cured product | KDM5A, PSMB5, CUL5 | HPGD 1322/4885TSHR 4872/4885MAPK1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.